ArticleiScience2026
Chronic chikungunya is associated with decreased anti-CHIKV antibody titers, neutralizing capacity, and antibody-dependent cellular cytotoxicity.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Infection due to the chikungunya virus (CHIKV) can cause chronic disease characterized by persistent arthralgia. While the humoral immune response to CHIKV is well characterized, the contribution of Fc-mediated effector functions in disease pathogenesis remains poorly understood. We assessed the quantitative and qualitative aspects of CHIKV-specific antibodies in patients with self-resolving or chronic chikungunya, including IgG/IgM titers and effector functions such as antibody-dependent cell phagocytosis (ADCP), complement deposition (ADCD), cell cytotoxicity (ADCC), and NK cell activation (ADNKA). Anti-CHIKV IgG and IgM titers declined between 3 and 6 months post-infection, and the lower titers at 6 months were associated with the chronic disease. The ADCP and ADCD capacities were similar between patients with self-resolving or chronic chikungunya. Patients with the chronic disease showed reduced ADCC but no reduced ADNKA. Females exhibited higher anti-CHIKV E2 antibody concentrations and ADCP. This study provides a comprehensive overview of Fc-mediated effector functions in chikungunya patients with differential disease outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.